Could personalized antibiotic dosing save lives in liver cirrhosis?
NCT ID NCT07612163
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is observing 1,000 people with liver cirrhosis who have bacterial infections and are being treated with β-lactam antibiotics. Researchers want to see how the body processes these drugs and whether personalized dosing could improve survival. The study is observational, meaning it watches what happens in real care rather than testing a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- β-lactam antibiotics
- What this could lead to
- If successful, this could lead to personalized antibiotic dosing for people with liver cirrhosis, potentially reducing deaths from infections.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test a new drug or directly improve outcomes. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, 210008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a simple blood test curb antibiotic overuse in sick kids?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Can liver damage predict how drugs behave?
- Better crystal ball for liver crisis: new scores put to the test
- Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test